11 results
The primary aim of the proposed study is to assess whether stenting for symptomatic vertebral artery stenosis >= 50% is feasible and safe. A secondary aim is to assess the rate of new vascular events in the territory of the vertebrobasilar…
To define indications for recently developed, but more expensive, self-expanding metal stents (SEMS) versus cheaper plastic stents in patients with primary or recurrent inoperable malignant extrahepatic common bile duct (CBD) obstruction, based on…
To determine the safety and effectiveness of Boston Scientific*s Everolimus-eluting coronary stent system (PROMUS Element*) for coronary revascularization in an unrestricted population compared to the Xience* Prime control.
The primary objective is to assess the safety and operation of the Stentys coronary stent system in patients with acute myocardial infarction compared with a balloon-expanding stent. These are the effect and safety in the short term (the procedure…
The objective for the study is to establish a proof of concept for the use of self-expandable stenting in subacute to chronic total occlusions and evaluate the safety and effectiveness of the STENTYS Coronary Stent System in the treatment of these…
The aim of this study is to determine safety, patency of placement and long term symptom-free outcome of a covered self expandable metal stent in patients with a benign CBD stricture.
The aim of this study is to determine safety, patency of placement and long term symptom-free outcome of a covered self expandable metal stent in patients with a benign CBD stricture.
Primary:*To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegalySecondary:*To investigate the safety and tolerability of a single dose of lanreotide PRF…
Primary Objective* To describe the antitumour efficacy of LAN monotherapy plus BSC every 28 days, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,…
Primary Objective• To assess superiority of treatment with CAM2029 compared to treatment with octreotide long-acting release (LAR) or lanreotide autogel (ATG) on progression-free survival (PFS) in patients with unresectable/metastatic and well-…
Primary objective: To evaluate the effect of navitoclax in combination with ruxolitinib on splenomegaly response when compared to ruxolitinib in subjects with myelofibrosis.Secondary objectives:• To evaluate the effect of navitoclax in combination…